Idenix Can Move Ahead On Studies Of HCV Candidate IDX184 With Partial Lifting Of FDA Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Company must negotiate future planned studies with FDA but has go-ahead for a biovailability study and then a Phase IIb trial.